JP2025020134A5 - - Google Patents

Download PDF

Info

Publication number
JP2025020134A5
JP2025020134A5 JP2024176901A JP2024176901A JP2025020134A5 JP 2025020134 A5 JP2025020134 A5 JP 2025020134A5 JP 2024176901 A JP2024176901 A JP 2024176901A JP 2024176901 A JP2024176901 A JP 2024176901A JP 2025020134 A5 JP2025020134 A5 JP 2025020134A5
Authority
JP
Japan
Prior art keywords
administered
pharmaceutical composition
dose
weeks
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024176901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025020134A (ja
Filing date
Publication date
Priority claimed from JP2020552872A external-priority patent/JP7119114B2/ja
Application filed filed Critical
Publication of JP2025020134A publication Critical patent/JP2025020134A/ja
Publication of JP2025020134A5 publication Critical patent/JP2025020134A5/ja
Pending legal-status Critical Current

Links

JP2024176901A 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法 Pending JP2025020134A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
US62/650,314 2018-03-30
JP2020552872A JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis
JP2022123689A JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023130117A Division JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法

Publications (2)

Publication Number Publication Date
JP2025020134A JP2025020134A (ja) 2025-02-12
JP2025020134A5 true JP2025020134A5 (enExample) 2025-03-12

Family

ID=66429483

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020552872A Active JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
JP2022123689A Active JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A Active JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法
JP2024176901A Pending JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2020552872A Active JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
JP2022123689A Active JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A Active JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法

Country Status (29)

Country Link
US (2) US12152072B2 (enExample)
EP (2) EP4327866B1 (enExample)
JP (4) JP7119114B2 (enExample)
KR (1) KR102552693B1 (enExample)
CN (1) CN111936165A (enExample)
AU (2) AU2019243283C1 (enExample)
BR (1) BR112020018099A2 (enExample)
CA (1) CA3095297A1 (enExample)
DK (1) DK3773715T3 (enExample)
EA (1) EA202091989A1 (enExample)
ES (1) ES2983809T3 (enExample)
FI (1) FI3773715T3 (enExample)
HR (1) HRP20240904T1 (enExample)
HU (1) HUE067445T2 (enExample)
IL (2) IL277514B2 (enExample)
LT (1) LT3773715T (enExample)
MA (1) MA52216B1 (enExample)
MD (1) MD3773715T2 (enExample)
MX (1) MX2020010269A (enExample)
MY (1) MY202368A (enExample)
PL (1) PL3773715T3 (enExample)
PT (1) PT3773715T (enExample)
RS (1) RS65661B1 (enExample)
SG (1) SG11202009526RA (enExample)
SI (1) SI3773715T1 (enExample)
TW (2) TWI837532B (enExample)
UA (1) UA128578C2 (enExample)
WO (1) WO2019191464A1 (enExample)
ZA (1) ZA202005388B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
US20210253690A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
BR112023013444A2 (pt) * 2021-01-06 2024-01-23 Abbvie Deutschland Métodos para tratar doença de crohn e colite ulcerativa
KR20240012469A (ko) * 2021-05-20 2024-01-29 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
CA3219846A1 (en) * 2021-05-28 2022-12-01 Venkatesh Krishnan Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
EP4623001A1 (en) * 2022-11-22 2025-10-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
AU2024236477A1 (en) 2023-03-10 2025-09-11 Eli Lilly And Company Methods of treating ulcerative colitis
TW202500185A (zh) * 2023-06-16 2025-01-01 大陸商信達生物製藥(蘇州)有限公司 重組抗白介素23p19亞基抗體在治療炎症性腸病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501537A1 (en) * 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗il−23抗体、組成物、方法および用途
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
US20190269757A1 (en) * 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

Similar Documents

Publication Publication Date Title
JP2025020134A5 (enExample)
JP2023166388A5 (enExample)
Zhang et al. Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential
Aho et al. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy
KR101718639B1 (ko) 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생
IL299376A (en) Fixed dose combination of pertuzumab plus transtuzumab
NZ598534A (en) Dosage regimen of an s1p receptor modulator
JP2013533858A5 (enExample)
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
MX2024006799A (es) Metodos para el tratamiento de cáncer con prame positivo.
JP2024016209A5 (enExample)
CN113274384A (zh) 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物
JP2023020885A5 (enExample)
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
Ogata et al. Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
Meuret et al. Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone
JPWO2022240688A5 (enExample)
CN109172550B (zh) 一种复合麻醉药物
CN108014337B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
KR20000005479A (ko) 약독화된 비면역원성 폭스 바이러스 또는 파라폭스 바이러스로부터 멀티포텐트 파라폭스 면역 유발인자의 약제로서 이용하는새로운 적용
JP2020524164A5 (enExample)
JPWO2020247774A5 (enExample)
Sood et al. Infantile pyoderma gangrenosum
CN112043718A (zh) 异甘草酸镁在制备治疗结肠炎药物中的应用
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn's disease